Clinical Trials

Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

By

Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.

Optical Probes That Illuminate Solid Tumors in Surgery Move One Step Closer to Reality

Optical Probes That Illuminate Solid Tumors in Surgery Move One Step Closer to Reality

By

Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.

Mapping Tumor Position During Lung Function Improves Radiation Therapy for Lung Cancer

Mapping Tumor Position During Lung Function Improves Radiation Therapy for Lung Cancer

By

A new clinical trial aims to apply advanced image analysis techniques to 4D CT scans. Already a standard step in targeting lung cancer radiotherapy, the trial seeks to use the scans map areas of lung function without additional testing.

Certain Characteristics of Clinical Trials May Predict Poor Accrual of Participants

By

Researchers identified characteristics that may lead to low patient accrual for a clinical trial.

No Need to Exclude Patients With Renal Insufficiency From Clinical Trials

By

Excluding patients with renal insufficiency but good performance status from clinical trials due to concern of excessive hematologic toxicity or poor outcomes may not be necessary with appropriate dosing modifications.

Mandatory Biopsy May Hinder Eligibility of Potential Participants in Cancer-related Clinical Trials

By

Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.

Pembrolizumab Increases Overall Survival for PD-L1-positive, Advanced Non-small Cell Lung Cancer

By

A recent study examined the efficacy of pembrolizumab for the treatment of previously treated, PD-L1-positive, advanced non-small-cell lung cancer.

Extra Biopsies in Clinical Trials Often Have No Impact on Drug Dose or Use in Cancer Treatments

By

Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.

Patient Education Prior to Oncologist Visit Improves Knowledge and Attitude Toward Clinical Trials

By

Patient education on clinical trials prior to the first oncologic visit improves knowledge, attitudes, and preparation for decision making about clinical trials.

ClinicalTrials.gov Shows NIH Funding On the Decline, Industry Funding On the Upswing

By

The number of registered NIH-funded trials listed on ClinicalTrials.gov decreased between 2006 through 2014; however, the number of industry-funded trials increased substantially.

International Effort Produces Risk Management Plan for Functional Imaging in Cancer Clinical Trials

By

A joint effort from the EORTC, the EANM, the ESR, and the US NCI has resulted in establishing a foundation to improve the implementation and use of imaging biomarkers in cancer clinical trials.

CAR T cells Can Have Powerful Activity in Multiple Myeloma

CAR T cells Can Have Powerful Activity in Multiple Myeloma

By

In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.

Investigational Immunotherapeutic Approach Increased Survival in Patients With Bladder Cancer

By

A novel immunotherapeutic approach improved outcomes for patients with advanced bladder cancer, according to a recent study.

Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)

By

More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.

Breakthrough Advance Announced in International Blood Cancer Drug Trial

By

Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.

Studies Demonstrate Clinical Advantages of Proton Therapy

Studies Demonstrate Clinical Advantages of Proton Therapy

By

The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.

Blood Test Could Match Cancer Patients to Best Treatments

By

Scientists have developed a blood test that could help pair cancer patients with the most suitable therapy for their disease, then track disease progression to see if the treatment is effective.

Patients With Lower Income Less Likely to Participate in Clinical Trials

By

Patients with newly diagnosed cancer were less likely to participate in clinical trials if their annual household income was less than $50,000.

Lower-Income Cancer Patients Show Decreased Trial Participation

Lower-Income Cancer Patients Show Decreased Trial Participation

Cancer trial participation decreases with decreasing annual household income, according to recent data.

Atezolizumab Set to Change Refractory Lung Cancer Treatment

Atezolizumab Set to Change Refractory Lung Cancer Treatment

By

Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.

Clinical Trial Demonstrates Superior Results With Immunotherapy vs Chemotherapy for Lung Cancer

By

An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.

Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL

Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL

By

ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.

Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab Vedotin

By

Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.

Clinical Trial Populations May Not Represent Patients Using Studied Medications

By

A recent study showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients who ultimately take the drugs, raising questions about the direct applicability of trial data.

Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions

Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions

By

Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.

Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung Cancers

Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung Cancers

By

Pembrolizumab, an immunotherapy drug that unmasks cancer cells allowing the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study presented at the 16th World Conference on Lung Cancer.

Long-term remissions achieved in first personalized cell therapy trial

By

Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.

Landmark basket study is changing how drug trials are conducted

Landmark basket study is changing how drug trials are conducted

By

Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

Two-cycle technique improves determining optimal treatment doses in clinical trials

By

A new technique has been developed by statisticians to help doctors optimize dosing new cancer treatments in phase I/II clinical trials.

Viral immunotherapy for skin cancer shows patient benefit in phase 3 trial

By

A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs